A method for designing a custom-made intra-oral appliance includes obtaining a virtual 3D reconstruction of an oral cavity, identifying an appliance region, obtaining a 3D appliance mesh from the appliance region, and processing the 3D appliance mesh for obtaining a volumetric appliance mesh. A method for obtaining a virtual 3D reconstruction of an oral cavity, the virtual 3D reconstruction being suitable for use in designing custom-made intra-oral appliances, and a method for designing an intra-oral appliance. The method for obtaining a virtual 3D reconstruction of an oral cavity includes obtaining at least one 2D image of an oral cavity, wherein the at least one image is acquired by a consumer electronics product, transforming the obtained at least one 2D image into an initial virtual 3D reconstruction of the oral cavity, and transferring information included in a further virtual 3D reconstruction to the initial virtual 3D reconstruction.
A61C 7/00 - Orthodontics, i.e. obtaining or maintaining the desired position of teeth, e.g. by straightening, evening, regulating, separating, or by correcting malocclusions
G06F 30/12 - Geometric CAD characterised by design entry means specially adapted for CAD, e.g. graphical user interfaces [GUI] specially adapted for CAD
2.
EFFECTS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND OF LSD ANALOGS TO ASSIST PSYCHOTHERAPY FOR GENERALIZED ANXIETY DISORDER OR OTHER ANXIETY NOT RELATED TO LIFE-THREATENING ILLNESS
A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and/or measures of depression (HDRS or BDI scores) and/or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Application software in the field of mobile operating systems (mobile application); software downloaded on the Internet; electronic publications (downloadable) provided online from databases or the Internet; software. Instruction and training services; computer-assisted training; organization and conducting of training workshops; dissemination of educational material; provision of training online; provision of training via a global computer network. Design and development of computer hardware and software for use in the medical field; medical research; scientific research services for medical purposes. Medical assistance; medical and health care clinic services; medical information; providing advice with respect to medical apparatus and instruments; provision of medical information; consulting services regarding medicine; medical assistance consultancy provided by doctors and other specialized medical personnel; public health consultancy; medical information services provided via the Internet; individual counseling and medical services provided to patients.
A composition including R-MDMA, S-MDMA, or specific (not 1:1 as in racemic MDMA) combinations of these two enantiomers of racemic MDMA as well as R-MDA, S-MDA, and a combination that is not 1:1 of R-MDA and S-MDA. A method of treating an individual, especially in substance-assisted psychotherapy by administering the composition to the individual. A method of personalized medicine, by evaluating an individual who is in need of MDMA treatment and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment, and administering the composition to the individual. A method of reducing abuse of MDMA by an individual, by administering R-MDMA to the individual and thereby reducing abuse.
An osteosynthesis plate as replacement of a synarthrosis includes two fixation plate segments for securing the osteosynthesis plate to two bones. The osteosynthesis plate has a connecting segment interconnecting the two fixation plate segments, the connecting segments protruding from the fixation plate segments.
Methods of assessing the pathological and/or physiological state of a subject, methods of monitoring a subject with heart failure or a subject that has been diagnosed as having or being at risk of having a condition associated with dyspnea and/or fatigue, and methods of diagnosing a subject as having decompensated heart failure are provided. The methods comprise obtaining a voice recording from a word-reading test from the subject, wherein the voice recording is from a word-reading test comprising reading a sequence of words drawn from a set of n words and analysing the voice recording, or a portion thereof. The analysing can comprise identifying a plurality of segments of the voice recording that correspond to single words or syllables; determining the value of one or more metrics selected from the breathing %, unvoicing/voicing ratio, voice pitch and correct word rate at least in part based on the identified segments; and comparing the value of the one or more metrics with one or more respective reference values. Related systems and products are also described.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G10L 25/18 - Speech or voice analysis techniques not restricted to a single one of groups characterised by the type of extracted parameters the extracted parameters being spectral information of each sub-band
G10L 25/21 - Speech or voice analysis techniques not restricted to a single one of groups characterised by the type of extracted parameters the extracted parameters being power information
G10L 25/66 - Speech or voice analysis techniques not restricted to a single one of groups specially adapted for particular use for comparison or discrimination for extracting parameters related to health condition
G10L 25/93 - Discriminating between voiced and unvoiced parts of speech signals
G10L 25/90 - Pitch determination of speech signals
Method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. Method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. Method of defining therapeutic doses of a psychedelic in clinical trials. Method of monitoring individuals for depression after treatment with LSD.
A method of dosing LSD in treating patients, by assessing genetic characteristics in the patient by identifying polymorphisms of CYP2D6 before use of a composition chosen from the group consisting of LSD, analogs thereof, derivatives thereof, and salts thereof, administering the composition to the patient based on the patient genetics, wherein a 50% dose is administered in a patient with non-functional CYP2D6 compared to a dose in functional CYP2D6 individuals, and producing maximum positive subjective acute effects in the patient and/or reducing anxiety and negative effects. A method of determining a preferred dose of LSD.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A composition including R-MDMA, S-MDMA, or specific (not 1:1 as in racemic MDMA) combinations of these two enantiomers of racemic MDMA as well as R-MDA, S-MDA, and a combination that is not 1:1 of R-MDA and S-MDA. A method of treating an individual, especially in substance-assisted psychotherapy by administering the composition to the individual. A method of personalized medicine, by evaluating an individual who is in need of MDMA treatment and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment, and administering the composition to the individual. A method of reducing abuse of MDMA by an individual, by administering R-MDMA to the individual and thereby reducing abuse.
A composition including R-MDMA, S-MDMA, or specific (not 1:1 as in racemic MDMA) combinations of these two enantiomers of racemic MDMA as well as R-MDA, S-MDA, and a combination that is not 1:1 of R-MDA and S-MDA. A method of treating an individual, especially in substance-assisted psychotherapy by administering the composition to the individual. A method of personalized medicine, by evaluating an individual who is in need of MDMA treatment and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment, and administering the composition to the individual. A method of reducing abuse of MDMA by an individual, by administering R-MDMA to the individual and thereby reducing abuse.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
11.
MDMA TREATMENT TO ENHANCE ACUTE EMOTIONAL EFFECTS PROFILE OF LSD, PSILOCYBIN OR OTHER PSYCHEDELICS
A method of enhancing positive effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a serotonergic psychedelic in the same dosage form or administered as separate compositions within a combination treatment schedule. A method of enhancing positive effects of a psychedelic, by inducing the release of endogenous monoamines, and subsequently stimulating 5-HT2A receptors.
A method of treating a patient with a psychedelic, by administering either a dose of LSD to the patient that is equivalent to a known dose of psilocybin with desired acute and therapeutic effects, or administering a dose of psilocybin to the patient that is equivalent to a known dose of LSD with desired acute and therapeutic effects. A method of treating a patient with LSD, by administering a dose of LSD to the patient equivalent to those of psilocybin known to be associated with positive long-term therapeutic outcomes. A method of determining a dose of a psychedelic or the dose-equivalence to another psychedelic to be administered to an individual, by administering a dose of a psychedelic to an individual, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual.
A method of treating a patient with a psychedelic, by administering either a dose of LSD to the patient that is equivalent to a known dose of psilocybin with desired acute and therapeutic effects, or administering a dose of psilocybin to the patient that is equivalent to a known dose of LSD with desired acute and therapeutic effects A method of treating a patient with LSD, by administering a dose of LSD to the patient equivalent to those of psilocybin known to be associated with positive long-term therapeutic outcomes. A method of determining a dose of a psychedelic or the dose-equivalence to another psychedelic to be administered to an individual, by administering a dose of a psychedelic to an individual, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual.
A method of inducing psychedelic states in an individual, by administering mescaline, a salt thereof, analogs thereof, or derivatives thereof to the individual, and inducing a psychedelic state in the individual. A method of therapy, by administering an intermediate “good effect dose” of mescaline, salt of mescaline, analogs thereof, or derivatives thereof to an individual, and inducing positive acute drug effects that are known to be associated with more positive long-term responses in psychiatric patients. A method of therapy, by administering an “ego-dissolution” dose of mescaline, a salt of mescaline, analogs thereof, or derivatives thereof to an individual, and providing the experience of ego-dissolution.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A method of dosing LSD in treating patients, by assessing genetic characteristics in the patient by identifying polymorphisms of CYP2D6 before use of a composition chosen from the group consisting of LSD, analogs thereof, derivatives thereof, and salts thereof, administering the composition to the patient based on the patient genetics, wherein a 50% dose is administered in a patient with non-functional CYP2D6 compared to a dose in functional CYP2D6 individuals, and producing maximum positive subjective acute effects in the patient and/or reducing anxiety and negative effects. A method of determining a preferred dose of LSD.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
18.
COMBINATION PRODUCT USING 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND CARVEDILOL FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
A composition for treating an individual while reducing acute adverse effects of an empathogen/entactogen, including effective amounts of the empathogen/entactogen and an adverse effect-reducing agent that blocks adverse effects of the empathogen/entactogen. A method of treating an individual with an empathogen/entactogen and reducing its acute adverse effects, by administering an empathogen/entactogen to the individual, administering an adverse effect-reducing agent to the individual, and reducing the acute adverse effects of the empathogen/entactogen. A method of stopping the acute cardiostimulant and hyperthermic action of an empathogen/entactogen in an individual, by administering an adverse effect-reducing agent to the individual after the individual has taken the empathogen/entactogen and stopping the acute adverse effects of the empathogen/entactogen. A method of treating an individual at risk of cardiovascular events and/or hyperthermia with an empathogen/entactogen.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
19.
COMBINATION PRODUCT USING 354-METHYLENEDS0XYMETHAMPHETASVSINE AND CARYEDILOL FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
A composition for treating an individual while reducing acute adverse effects of an empathogen/entactogen, including effective amounts of the empathogen/entactogen and an adverse effect-reducing agent that blocks adverse effects of the empathogen/entactogen. A method of treating an individual with an empathogen/entactogen and reducing its acute adverse effects, by administering an empathogen/entactogen to the individual, administering an adverse effect-reducing agent to the individual, and reducing the acute adverse effects of the empathogen/entactogen. A method of stopping the acute cardlostimulant and hyperthermic action of an empathogen/entactogen in an individual, by administering an adverse effect-reducing agent to the individual after the individual has taken the empathogen/entactogen and stopping the acute adverse effects of the empathogen/entactogen, A method of treating an individual at risk of cardiovascular events and/or hyperthermia with an empathogen/entactogen.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61P 39/00 - General protective or antinoxious agents
20.
Devices and Methods for Determining Heart Function of a Living Subject
The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described.
The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described.
The invention further relates to complementary parts of such systems that work best in combination.
The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described.
The invention further relates to complementary parts of such systems that work best in combination.
Medical catheters, sheaths and shafts are disclosed that carry an arrangement of integrated digital sensor systems-on-chip (SoC) in the portion thereof residing inside the body. These devices combine at their portion that resides inside the body, the complete chain of signal transduction, signal analog-to-digital conversion and digital signal transmission, and allow to acquire single and multiple physical entities in a single setup. In specific instances the devices integrate wireless data transfer functionality, and in specific instances they integrate wireless energy harvesting for battery-free functionality.
The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described.
The invention further relates to complementary parts of such systems that work best in combination.
Medical catheters, sheaths and shafts are disclosed that carry an arrangement of integrated digital sensor systems-on-chip (SoC) in the portion thereof residing inside the body. These devices combine at their portion that resides inside the body, the complete chain of signal transduction, signal analog-to-digital conversion and digital signal transmission, and allow to acquire single and multiple physical entities in a single setup. In specific instances the devices integrate wireless data transfer functionality, and in specific instances they integrate wireless energy harvesting for battery-free functionality.
The present invention further describes complementary monitor systems that are suited for reception, processing and analysis of data acquired by such catheters/sheaths/shafts to yield a robust assessment of cardiac performance.
The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described.
The invention further relates to complementary parts of such systems that work best in combination.
Medical catheters, sheaths and shafts are disclosed that carry an arrangement of integrated digital sensor systems-on-chip (SoC) in the portion thereof residing inside the body. These devices combine at their portion that resides inside the body, the complete chain of signal transduction, signal analog-to-digital conversion and digital signal transmission, and allow to acquire single and multiple physical entities in a single setup. In specific instances the devices integrate wireless data transfer functionality, and in specific instances they integrate wireless energy harvesting for battery-free functionality.
The present invention further describes complementary monitor systems that are suited for reception, processing and analysis of data acquired by such catheters/sheaths/shafts to yield a robust assessment of cardiac performance.
Moreover, the present invention relates to innovations which render such systems applicable to patients with and without cardiac assist devices.
A61M 60/135 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel inside a blood vessel, e.g. using grafting
A61M 60/871 - Energy supply devicesConverters therefor
A method of dosing LSD in treating patients, by assessing genetic characteristics in the patient before LSD use, administering LSD to the patient based on the patient genetics, and producing maximum positive subjective acute effects in the subject and/or reducing anxiety and negative effects. A method of determining a preferred dose of LSD, by determining metabolic and genetic markers in a patient (such as by assessing CYP2D6 activity and/or assessing 5HTR1A rs6295 and 5HTR2A rs6313 genotypes in a patient), adjusting a dose of LSD based on the metabolic activity and genetic profile, administering the dose of LSD to the patient, and producing maximum positive subjective acute effects in the subject and/or reducing anxiety and negative effects. A method of determining a dose of LSD based on an assessment of the presence of CYP2D6 inhibitors.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/26 - Psychostimulants, e.g. nicotine, cocaine
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
22.
OSTEOSYNTHESIS PLATE SUITABLE AS REPLACEMENT OF A SYNARTHROSIS
The invention relates to an osteosynthesis plate (1) as replacement of a synarthrosis, the osteosynthesis plate (1) comprising two fixation plate segments (2, 3) for securing the osteosynthesis plate (1) to two bones, wherein the osteosynthesis plate (1) has a connecting segment (4) which interconnects the two fixation plate segments, the connecting segments protruding from the fixation plate segments.
A method of dosing LSD in treating patients, by assessing genetic characteristics in the patient before LSD use, administering LSD to the patient based on the patient genetics, and producing maximum positive subjective acute effects in the subject and/or reducing anxiety and negative effects. A method of determining a preferred dose of LSD, by determining metabolic and genetic markers in a patient (such as by assessing CYP2D6 activity and/or assessing 5HTR1A rs6295 and 5HTR2A rs6313 genotypes in a patient), adjusting a dose of LSD based on the metabolic activity and genetic profile, administering the dose of LSD to the patient, and producing maximum positive subjective acute effects in the subject and/or reducing anxiety and negative effects. A method of determining a dose of LSD based on an assessment of the presence of CYP2D6 inhibitors.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
24.
EFFECTS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND OF LSD ANALOGS TO ASSIST PSYCHOTHERAPY FOR GENERALIZED ANXIETY DISORDER OR OTHER ANXIETY NOT RELATED TO LIFE-THREATENING ILLNESS
A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and/or measures of depression (HDRS or BDI scores) and/or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A method of inducing psychedelic states in an individual, by administering mescaline, a salt thereof, analogs thereof, or derivatives thereof to the individual, and inducing a psychedelic state in the individual. A method of therapy, by administering an intermediate "good effect dose" of mescaline, salt of mescaline, analogs thereof, or derivatives thereof to an individual, and inducing positive acute drug effects that are known to be associated with more positive long-term responses in psychiatric patients. A method of therapy, by administering an "ego-dissolution" dose of mescaline, a salt of mescaline, analogs thereof, or derivatives thereof to an individual, and providing the experience of ego-dissolution.
A method of inducing psychedelic states in an individual, by administering mescaline, a salt thereof, analogs thereof, or derivatives thereof to the individual, and inducing a psychedelic state in the individual. A method of therapy, by administering an intermediate “good effect dose” of mescaline, salt of mescaline, analogs thereof, or derivatives thereof to an individual, and inducing positive acute drug effects that are known to be associated with more positive long-term responses in psychiatric patients. A method of therapy, by administering an “ego-dissolution” dose of mescaline, a salt of mescaline, analogs thereof, or derivatives thereof to an individual, and providing the experience of ego-dissolution.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61P 25/00 - Drugs for disorders of the nervous system
27.
EFFECTS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND OF LSD ANALOGS TO ASSIST PSYCHOTHERAPY FOR GENERALIZED ANXIETY DISORDER OR OTHER ANXIETY NOT RELATED TO LIFE-THREATENING ILLNESS
A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and/or measures of depression (HDRS or BDI scores) and/or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.
Methods of assessing the pathological and/or physiological state of a subject, methods of monitoring a subject with heart failure or a subject that has been diagnosed as having or being at risk of having a condition associated with dyspnea and/or fatigue, and methods of diagnosing a subject as having decompensated heart failure are provided. The methods comprise obtaining a voice recording from a word-reading test from the subject, wherein the voice recording is from a word-reading test comprising reading a sequence of words drawn from a set of n words and analysing the voice recording, or a portion thereof. The analysing can comprise identifying a plurality of segments of the voice recording that correspond to single words or syllables; determining the value of one or more metrics selected from the breathing %, unvoicing/voicing ratio, voice pitch and correct word rate at least in part based on the identified segments; and comparing the value of the one or more metrics with one or more respective reference values. Related systems and products are also described.
G10L 25/66 - Speech or voice analysis techniques not restricted to a single one of groups specially adapted for particular use for comparison or discrimination for extracting parameters related to health condition
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A method of measuring and identifying LSD and its major metabolite O-H-LSD, by obtaining a sample from an individual, and measuring, identifying, and quantifying LSD and O-H-LSD in the sample by performing a LC-MS/MS analysis. A method of treating and monitoring individuals taking LSD, by administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual, monitoring the individual by obtaining a sample from an individual and measuring and identifying the analytes in the sample by performing a LC-MS/MS analysis, and adjusting the microdose based on the amount of LSD quantified in the LC-MS/MS analysis. A method of adjusting dosing of LSD, by administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual, and adjusting the microdose based on blood concentration analytics.
A method of measuring and identifying LSD and its major metabolite O-H-LSD, by obtaining a sample from an individual, and measuring, identifying, and quantifying LSD and O-H-LSD in the sample by performing a LC-MS/MS analysis. A method of treating and monitoring individuals taking LSD, by administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual, monitoring the individual by obtaining a sample from an individual and measuring and identifying the analytes in the sample by performing a LC-MS/MS analysis, and adjusting the microdose based on the amount of LSD quantified in the LC-MS/MS analysis. A method of adjusting dosing of LSD, by administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual, and adjusting the microdose based on blood concentration analytics.
A method of enhancing positive therapeutic effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen of MDMA administered in a dose of 20-200 mg, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a psychedelic in the same dosage form.
The present invention relates to the use of SGLT-2 inhibitors and/or an interleukin-1-receptor antagonist or a non-agonist antibody reactive to IL-1 or IL-1R in the treatment of prevention of symptomatic hypoglycaemia after bariatric surgery.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
33.
METHOD OF QUANTIFYING PSILOCYBIN'S MAIN METABOLITES, PSILOCIN AND 4-HYDROXYINDOLE-3-ACETIC ACID, IN HUMAN PLASMA
A method of measuring and identifying metabolites of a tryptamine compound, by obtaining a sample from an individual, and measuring and identifying metabolites of the tryptamine compound in the sample by performing a LC-MS/MS analysis. A method of adjusting dosing in patients with tryptamine compound-assisted psychotherapy in therapeutic drug monitoring (TDM), by obtaining a sample from an individual, measuring and identifying metabolites of the tryptamine compounds in the sample by performing a LC-MS/MS analysis, and adjusting a dose of the tryptamine compounds based on the measured metabolites.
A method of inducing a psychedelic state in an individual by administering DMT, a salt of DMT, analogs thereof, or derivatives thereof to an individual with a continuous perfusion system and inducing a psychedelic state. A method of inducing a psychedelic state in an individual safely, by administering DMT, a salt of DMT, analogs thereof, or derivatives thereof to an individual with a continuous perfusion system, inducing a psychedelic state, and adjusting or ending the psychedelic state on demand. A method of providing a short lasting psychedelic treatment of minutes to 1-2 hours, by administering DMT, a salt of DMT, analogs thereof, or derivatives thereof to an individual with a continuous perfusion system and providing psychedelic treatment for minutes to 1-2 hours. A method of determining a dose of DMT for an individual.
A method of inducing a psychedelic state in an individual by administering DMT, a salt of DMT, analogs thereof, or derivatives thereof to an individual with a continuous perfusion system and inducing a psychedelic state. A method of inducing a psychedelic state in an individual safely, by administering DMT, a salt of DMT, analogs thereof, or derivatives thereof to an individual with a continuous perfusion system, inducing a psychedelic state, and adjusting or ending the psychedelic state on demand. A method of providing a short lasting psychedelic treatment of minutes to 1-2 hours, by administering DMT, a salt of DMT, analogs thereof, or derivatives thereof to an individual with a continuous perfusion system and providing psychedelic treatment for minutes to 1-2 hours. A method of determining a dose of DMT for an individual.
A method of dosing an empathogen/entactogen in treating patients, by assessing patient characteristics before empathogen/entactogen use, administering empathogen/entactogen to the patient based on the patient characteristics, and producing maximum positive subjective acute effects in the patient. A method of determining a dose of an empathogen/entactogen based on body weight, sex, and CYP2D6 activity by assessing patient characteristics of body weight, sex, and CYP2D6 activity before empathogen/entactogen use, administering the empathogen/entactogen to the patient based on the patient characteristics, and producing maximum positive subjective acute effects in the patient. A method of refining dosing of an empathogen/entactogen. A method of predicting future dosing with an empathogen/entactogen. A method of evaluating feasibility of patients to receive an empathogen/entactogen as treatment. A method of optimizing empathogen/entactogen treatment in a patient.
A method of dosing an empathogen/entactogen in treating patients, by assessing patient characteristics before empathogen/entactogen use, administering empathogen/entactogen to the patient based on the patient characteristics, and producing maximum positive subjective acute effects in the patient. A method of determining a dose of an empathogen/entactogen based on body weight, sex, and CYP2D6 activity by assessing patient characteristics of body weight, sex, and CYP2D6 activity before empathogen/entactogen use, administering the empathogen/entactogen to the patient based on the patient characteristics, and producing maximum positive subjective acute effects in the patient. A method of refining dosing of an empathogen/entactogen. A method of predicting future dosing with an empathogen/entactogen. A method of evaluating feasibility of patients to receive an empathogen/entactogen as treatment. A method of optimizing empathogen/entactogen treatment in a patient.
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
38.
SGLT-2 INHIBITORS OR IL-1R ANTAGONISTS FOR REDUCTION OF HYPOGLYCAEMIA IN PREDIABETES
The present invention relates to the use of SGLT-2 inhibitors and/or interleukin-1-receptor antagonists or non-agonist antibodies reactive to interleukin-1β or IL-1 receptor and IL-1 accessory protein in the treatment of prevention of postprandial (or reactive) hypoglycaemia in prediabetes.
A method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. A method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. A method of defining therapeutic doses of a psychedelic in clinical trials. A method of monitoring individuals for depression after treatment with LSD.
A method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. A method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. A method of defining therapeutic doses of a psychedelic in clinical trials. A method of monitoring individuals for depression after treatment with LSD.
A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing its acute duration of action, by administering a psychedelic drug to the individual, administering a duration shortening agent to the individual, and shortening and/or reducing the acute effects of the psychedelic drug. A method of stopping the acute duration of action of a psychedelic drug in an individual, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug and stopping the acute effects of the psychedelic drug.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine
A61P 25/26 - Psychostimulants, e.g. nicotine, cocaine
44.
CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION
A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing its acute duration of action, by administering a psychedelic drug to the individual, administering a duration shortening agent to the individual, and shortening and/or reducing the acute effects of the psychedelic drug. A method of stopping the acute duration of action of a psychedelic drug in an individual, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug and stopping the acute effects of the psychedelic drug.
The present invention relates to a method for predicting whether a subject to be treated for monosymptomatic nocturnal enuresis will respond to said treatment, wherein the method comprises determining a first level (cl) of prepro-vasopressin (prepro-AVP) or a fragment thereof in a first sample of said subject which has been obtained at a first time, determining a second level (c2) of prepro-vasopressin (prepro-AVP) or said fragment thereof in a second sample of said subject which has been obtained at a second time.
The present invention relates to the use of SGLT-2 inhibitors and/or an interleukin- 1-receptor antagonist or a non-agonist antibody reactive to IL-1 or IL-1R in the treatment of prevention of symptomatic hypoglycaemia after bariatric surgery.
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61P 41/00 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
A protective device for open heart aortic valve replacement surgery in a patient, comprises a base element (2) having, on its proximal side (4), a first coupling member (10) and, on its distal side (6), a second coupling member (12). Moreover, the device comprises a longitudinally slidable elongated actuator member (14) distally provided with a third coupling member (18), a tip element (20) comprising a fourth coupling member (22) releasably connectable with the second coupling member (12) and a fifth coupling member (24) releasably connectable with the third coupling member (18). A flexible strut arrangement (26) forms a radially external connection between the base element (2) and the tip element (20), with a screen element (28) surroundingly attached to the strut arrangement (26). An elongated handling member (30) has a distal end (32) provided with a sixth coupling member (34) releasably connectable with the first coupling member (10), the handling member (30) having a longitudinal passageway (36) configured to slidingly receive the actuator member (14). In a deployed state of the device, the fourth coupling member (22) is connected with the second coupling member (12) and the strut arrangement (26) is radially expanded, thereby forming an anchoring support for attachment to a surrounding arterial wall segment (W) of the patient. In a movable state of the device, the fourth coupling member (22) is released from the second coupling member (12) and the tip element (20) is maintained distally displaced from the base element (2), whereby the strut arrangement (26) is longitudinally expanded so as to be movable within the surrounding arterial wall segment (W) and through the aortic valve of the patient.
A61B 17/221 - Calculus gripping devices in the form of loops or baskets
A61F 2/966 - Instruments specially adapted for placement or removal of stents or stent-grafts having an outer sleeve with relative longitudinal movement between outer sleeve and prosthesis, e.g. using a push rod
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Scientific research for medical purposes; conducting of
clinical studies and clinical trials; quality control
testing; certification (quality control); provision of
advice relating to quality control; testing services for
certification of quality or standards; storage of
information in databases. Medical information; medical services; providing health
care information; services provided by professional
consultants in all fields of surgical, orthopedic, surgical
treatment, medical technology and anesthesiology services;
medical information services provided via the Internet;
services provided by consultants in medicine; clinic and
hospital services.
49.
Devices and methods for determining heart function of a living subject
The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described.
The invention further relates to complementary parts of such systems that work best in combination.
Medical catheters, sheaths and shafts are disclosed that carry an arrangement of integrated digital sensor systems-on-chip (SoC) in the portion thereof residing inside the body. These devices combine at their portion that resides inside the body, the complete chain of signal transduction, signal analog-to-digital conversion and digital signal transmission, and allow to acquire single and multiple physical entities in a single setup. In specific instances the devices integrate wireless data transfer functionality, and in specific instances they integrate wireless energy harvesting for battery-free functionality.
The present invention further describes complementary monitor systems that are suited for reception, processing and analysis of data acquired by such catheters/sheaths/shafts to yield a robust assessment of cardiac performance.
Moreover, the present invention relates to innovations which render such systems applicable to patients with and without cardiac assist devices.
A61M 60/135 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel inside a blood vessel, e.g. using grafting
A61M 60/871 - Energy supply devicesConverters therefor
A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Scientific research for medical purposes; conducting of clinical studies in the nature of clinical research and clinical trials for others in the field of perioperative medicine and outcome research; quality control testing, namely, quality control for others; testing, analysis and evaluation of the goods and services of others to determine conformity with certification standards; provision of advice relating to quality control; testing services for certification of quality or standards, namely, testing, analysis and evaluation of the services of others to determine conformity with certification standards; temporary electronic storage of information in databases Medical information; medical services; providing health care information by print media, telephone, global computer networks and electronic means; consulting services in the fields of surgery, orthopedics, surgical treatment, anesthesiology and perioperative medicine; medical information services provided via the Internet; consulting services in the field medicine; medical clinic and hospital services
The invention relates to an artificial vascular graft comprising a primary scaffold structure encompassing an inner space of the artificial vascular graft, said primary scaffold structure having an inner surface facing towards said inner space and an outer surface facing away from said inner space, a coating on said inner surface, wherein a plurality of grooves is comprised in said coating of said inner surface. The primary scaffold structure comprises further a coating on said outer surface. The primary scaffold structure and the coating on said inner surface and on said outer surface are d designed in such a way that cells, in particular progenitor cells, can migrate from the periphery of said artificial vascular graft through said outer surface of said coating, said primary scaffold structure and said inner surface to said inner space, if the artificial vascular graft is used as intended. The invention relates further to a method for providing said graft.
A61F 2/90 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
The invention relates to a method of in vitro culturing or expanding human or animal tissue (2, 2′). The method comprises: obtaining a sample of human or animal tissue; downsizing tissue (21, 21′) of the sample; generating an assembly by placing the downsized tissue on a scaffold or hydrogel (22, 22′); arranging the assembly inside a culture chamber of a 3D perfusion system (23, 23′); and perfusing the assembly in the 3D perfusion system for a predefined time (24, 24′). The method according to the invention allows for preparing and directly culturing in vitro fresh tissue specimens for a high efficient in vitro culturing using a perfused bioreactor system. As single cells of tissue are in most cases undergoing to an in vitro cell-death due to missing micro environmental signals, the use of downsized tissue, comprising cell clumps and tissue fragments of hundreds of cells, may help to prevent cell death in vitro as well as to maintain the initial heterogeneous tissue microenvironment consisting of specific cell types such as epithelial, stromal and immune cells together. Thus, the method according to the invention is capable of efficiently culturing the whole tissue over time, thus allowing for survival of original cell types.
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (Germany)
Inventor
Bieri, Oliver
Ganter, Carl
Abstract
A post-processing method for regularizing the phase information of magnetic resonance (MR) related imaging data is provided. According to this method the values of a first phase information map obtained from at least one MR image are used for the calculation of a regularized second phase information map. In doing so, the values of the second phase information map are represented by a truncated Fourier expansion with coefficients that are determined from the first phase information map by means of a least squared minimization. In a further aspect, the invention provides a method for water/fat- decomposition of multi-echo MRI data, wherein a maximum likelihood estimation is made by means of minimizing a function chi square for determining the complex water and fat signal amplitudes a and b of the water and the fat signal, respectively, wherein the estimation is simplified by minimizing chi square separately with respect to the derivatives of a and b.
The invention relates to a container and a system for the storage of at least parts of an object in a liquid medium, in particular for the storage of guide wires for medical use. A container (10) for the storage of at least parts of an object in a liquid medium is provided, in particular for the storage of guide wires for medical use. It comprises a space (12) for retaining a liquid medium, an opening (14) and a holding element (20) for holding said object within said container (10). Said holding element (20) at least partly overlaps said opening (14) and comprises an area (22) facing said opening (14). Said holding element (20) is firmly attached to a wall element (33) of the container (10) and comprises a form element (24) which extends from said area (22) towards said opening (14) with at least one component of its direction of extension.
The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described. The invention further relates to complementary parts of such systems that work best in combination. Medical catheters, sheaths and shafts are disclosed that carry an arrangement of integrated digital sensor systems-on-chip (SoC) in the portion thereof residing inside the body. These devices combine at their portion that resides inside the body, the complete chain of signal transduction, signal analog-to-digital conversion and digital signal transmission, and allow to acquire single and multiple physical entities in a single setup. In specific instances the devices integrate wireless data transfer functionality, and in specific instances they integrate wireless energy harvesting for battery- free functionality. The present invention further describes complementary monitor systems that are suited for reception, processing and analysis of data acquired by such catheters/sheaths/shafts to yield a robust assessment of cardiac performance. Moreover, the present invention relates to innovations which render such systems applicable to patients with and without cardiac assist devices.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/091 - Measuring volume of inspired or expired gases, e.g. to determine lung capacity
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
The preparation of poly-2-oxazoline amphiphilic polymers and copolymers is described. Self-assembled particles comprising these amphiphilic polymers and which are useful for the targeted delivery of therapeutic and diagnostic agents are also described.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
58.
Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
2 is a moiety capable of selectively binding to a biomolecule, or a nanoparticle. The invention further relates to complexes of the ligand, particularly radionuclides and their use in radioimmunotherapy and imaging.
C08G 69/08 - Polyamides derived from amino carboxylic acids or from polyamines and polycarboxylic acids derived from amino carboxylic acids
C08G 69/48 - Polymers modified by chemical after-treatment
C08G 69/26 - Polyamides derived from amino carboxylic acids or from polyamines and polycarboxylic acids derived from polyamines and polycarboxylic acids
C07C 235/74 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
The invention relates to an artificial vascular graft comprising a primary scaffold structure encompassing an inner space of the artificial vascular graft, said primary scaffold structure having an inner surface facing towards said inner space and an outer surface facing away from said inner space, a coating on said inner surface, wherein a plurality of grooves is comprised in said coating of said inner surface. The primary scaffold structure comprises further a coating on said outer surface. The primary scaffold structure and the coating on said inner surface and on said outer surface are d designed in such a way that cells, in particular progenitor cells, can migrate from the periphery of said artificial vascular graft through said outer surface of said coating, said primary scaffold structure and said inner surface to said inner space, if the artificial vascular graft is used as intended. The invention relates further to a method for providing said graft.
A61F 2/90 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
The preparation of poly-2-oxazoline amphiphilic polymers and copolymers is described. Self-assembled particles comprising these amphiphilic polymers and which are useful for the targeted delivery of therapeutic and diagnostic agents are also described.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
61.
METHODS FOR DETECTING NEURODEGENERATIVE PROTEINOPATHIES
The present invention relates to methods for detecting neurodegenerative disorders, in particular for detecting neurodegenerative proteinopathies such as neurodegenerative tauopathies.
The invention relates to a method of in vitro culturing or expanding human or animal tissue (2, 2'). The method comprises: obtaining a sample of human or animal tissue; downsizing tissue (21, 21') of the sample; generating an assembly by placing the downsized tissue on a scaffold or hydrogel (22, 22'); arranging the assembly inside a culture chamber of a 3D perfusion system (23, 23'); and perfusing the assembly in the 3D perfusion system for a predefined time (24, 24'). The method according to the invention allows for preparing and directly culturing in vitro fresh tissue specimens for a high efficient in vitro culturing using a perfused bioreactor system. As single cells of tissue are in most cases undergoing to an in vitro cell-death due to missing micro environmental signals, the use of downsized tissue, comprising cell clumps and tissue fragments of hundreds of cells, may help to prevent cell death in vitro as well as to maintain the initial heterogeneous tissue microenvironment consisting of specific cell types such as epithelial, stromal and immune cells together. Thus, the method according to the invention is capable of efficiently culturing the whole tissue over time, thus allowing for survival of original cell types.
The disclosure relates to an agonist of CDIc-restricted T cells or an agonist-specific-CDIc-restricted T cell, their medical and diagnostic uses and compositions comprising the same. In particular the agonist is a lipid antigen.
The invention relates to octadentate ligands of a general formula R1 - D - X - D - X - D - X - D - E - R2, wherein D is C(O)N(OH) or N(OH)C(O), pyrimidinone or pyridinone, each X independently of any other X is a saturated or partially unsaturated, substituted or unsubstituted linker comprising 8-11 atoms selected from any of N, C, O; R1 is alkyl, cycloalkyl, arene, or heteroarene, E is a saturated or partially unsaturated, substituted or unsubstituted chain comprising 1 - 50 atoms and R2 is a moiety capable of selectively binding to a biomolecule, or a nanoparticle. The invention further relates to complexes of the ligand, particularly radionuclides and their use in radioimmunotherapy and imaging.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (Germany)
UNIVERSITÄTSSPITAL BASEL (Switzerland)
Inventor
Seeberger, Peter H.
Stallforth, Pierre
De Libero, Gennaro
Cavallari, Marco
Abstract
The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.
A method of controlling a surgical intervention to a bone (31) comprises: obtaining a three-dimensional image or multiplanar reconstruction of the bone (31), defining a position and an axis of intervention on the three-dimensional image or multiplanar reconstruction of the bone (31), and controlling the orientation of an intervention instrument (1) equipped with an orientation sensor (2) during the surgical intervention by evaluating a signal provided by the orientation sensor (2). The method further comprises referencing the intervention instrument (1) with respect to the bone (31) before the surgical intervention by arranging the intervention instrument (1) along an anatomic landmark (32) being an edge of the bone (31) and rotating the orientation sensor (2) into a predefined position, or by arranging the intervention instrument (1) essentially perpendicular to an anatomic landmark (32) being an essentially flat surface of the bone (31) and rotating the orientation sensor (2) into a predefined position. The method according to the invention allows for efficiently achieving correct orientation and position of the intervention instrument in a bone surgical intervention. Furthermore, the method according to the invention provides an efficient real-time control at comparably low efforts. Still further, with the method according to the invention radiation exposure to the operational staff as well as patients can be reduced.
A61B 19/00 - Instruments, implements or accessories for surgery or diagnosis not covered by any of the groups A61B 1/00-A61B 18/00, e.g. for stereotaxis, sterile operation, luxation treatment, wound edge protectors(protective face masks A41D 13/11; surgeons' or patients' gowns or dresses A41D 13/12; devices for carrying-off, for treatment of, or for carrying-over, body liquids A61M 1/00)
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/56 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor
The invention relates to an artificial vascular graft comprising a primary scaffold structure encompassing an inner space of the artificial vascular graft, said primary scaffold structure having an inner surface facing towards said inner space and an outer surface facing away from said inner space, a coating on said inner surface, wherein a plurality of grooves is comprised in said coating of said inner surface. The primary scaffold structure comprises further a coating on said outer surface. The primary scaffold structure and the coating on said inner surface and on said outer surface are d designed in such a way that cells, in particular progenitor cells, can migrate from the periphery of said artificial vascular graft through said outer surface of said coating, said primary scaffold structure and said inner surface to said inner space, if the artificial vascular graft is used as intended. The invention relates further to a method for providing said graft.
Implant system for a total ankle replacement, comprising: a tibial implant (1) being designed to be fastened to a distal end (4) of the tibia (T), as well as particularly an intermediate implant (2) and a talar implant (3). According to the invention a separate locking device (11) is provided being designed to be inserted into a first recess (R) of the tibia (T) extending along said distal end (4) of the tibia (T), wherein the tibial implant (1) comprises a peg (12) protruding from a base (1a) of the tibial implant (1), which peg (12) is designed to be inserted into a second recess (R') in said distal end (4) of the tibia (T), which second recess (R') particularly communicates with the first recess (R'), and wherein when the locking device (11) is inserted into the first recess (R) and the peg (12) is inserted into the second recess (R') the locking device (11) is designed to fasten the peg (12) and thereby the tibial implant (1) to the locking device (11).
Injectable hydrogels comprising polysaccharides based on disaccharides the backbones of which form an α-helix structure and in which in atleast 10% of the disaccharide units the primary hydroxyl groups are oxidized.
G01V 3/00 - Electric or magnetic prospecting or detectingMeasuring magnetic field characteristics of the earth, e.g. declination or deviation
G01R 33/44 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
The present invention relates to methods for detecting inflammatory disorders and more particularly to methods for detecting inflammatory disorders by detecting cell-free nucleosomes in a serum sample isolated from a subject.
The present invention relates to a method for the simultaneous amplification of a plurality of different nucleic acid target sequences comprising the steps of providing a plurality of different nucleic acid polymers as templates, each template comprising a specific target sequence and a primer annealing sequence located downstream of the target sequence, and amplifying the template by a polymerase dependent amplification reaction using a primer oligonucleotide comprising a primer sequence which is at least essentially complementary to the primer annealing sequence. The method is characterized in that for the polymerase dependent amplification reaction a set of primer oligonucleotides is used, said set comprising at least two primer oligonucleotides which are able to anneal to the primer annealing sequence of the same template and which differ from each other in the efficiency for the polymerase dependent amplification reaction to take place.
The invention relates to mesenchymal stem cell comprising a first transgene encoding a mammalian telomerase, and a second transgene encoding a fusion protein constituted of a monomer of a protein able to induce apoptosis in said mesenchymal stem cell in dimeric form, and a protein able to bind to a small molecule pharmaceutical drug, wherein said fusion molecule is able to dimerize and trigger apoptosis in said mesenchymal stem cell when said cell is exposed to said small molecule pharmaceutical drug. The invention further relates to methods of generating such cell, and its use in providing devitalized tissue matrices for transplantation.
The invention relates to Implant device (1) comprising a rigid element (10) being designed to be fastened to a femur implant (20) in a fastened state of said rigid element (10), wherein particularly said femur implant (20) is an intramedullary nail or a femoral stem. According to the invention said rigid element (10) is designed as a hook-shaped plate (10) for encompassing the greater trochanter (3) of the femur (2) at least in sections when being arranged in said fastened state and when said femur implant (20) is arranged in or on the femur (2) as intended.
The present invention relates to a porous hyaluronic acid/fibrin-based bioactive material with controlled release at topical level of an anti-angiogenic drug (bevacizumab) for applications in the field of the regeneration of cartilage and a process for its production, scaffold and constructs obtained from said material.
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E. V. (Germany)
UNIVERSITÄTSSPITAL BASEL (Switzerland)
Inventor
Seeberger, Peter H.
Stallforth, Pierre
Delibero, Gennaro
Cavallari, Marco
Abstract
The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure wherein a carbohydrate antigen is covalently bound to a glycolipid adjuvant. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (Germany)
UNIVERSITÄTSSPITAL BASEL (Switzerland)
Inventor
Seeberger, Peter H.
Stallforth, Pierre
De Libero, Gennaro
Cavallari, Marco
Abstract
The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi- modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (France)
UNIVERSITATSSPITAL BASEL (Switzerland)
Inventor
Biot, Claire
Albert, Matthew
Rentsch, Cyrill
Gsponer, Joël
Abstract
A first and a second identical or different mycobacterial immunogenic compositions, each comprising at least a Mycobacterium bovis bacillus Calmette-Guerin (BCG), an antigenically related non-pathogenic mycobacteria, or one or more immunogenic component(s) thereof, as therapeutic active ingredient(s) for use in the treatment of cancer by parenteral or oral administration of the first composition to a cancer patient before local administration of the second composition at tumor site. A method in vitro for monitoring cancer treatment by immunotherapy with BCG, antigenically related non-pathogenic mycobacteria, or immunogenic component(s) thereof, comprising assaying BCG-specific immune response in a patient.
The present invention relates to a ring (1) for implantation in patients receiving stoma having (1) an inner ring (2) suitable for fitting an abdominal wall on its outer circumference having an opening (3) suitable for an abdominal organ to pass through the ring to the exterior side (5) and (ii) a lip seal (4) extending over the interior side (5) of the inner ring (2) to seal the stoma opening for use in abdominal surgery. In addition, the present invention is directed to a method of treatment, comprising the surgical introduction of a ring (1) of the invention into the abdominal wall of a mammal in need of abdominal, preferably stoma surgery.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
The invention relates to a crutch (1) for a forearm (F) of a person for supporting said person, comprising: a longitudinally extending member (20) having a floor-engaging first free end (21), a handle (30) connected to said longitudinally extending member (20), which handle (30) is designed to be manually graspable by said person, and a cuff (10) connected to said longitudinally extending member (20), which cuff (10) forms a contact surface (10a) that is designed to support said forearm, when said handle (30) is held by a hand (H) associated to said forearm (F). According to the invention, the contact surface (10a) comprises a particularly vertical recess, particularly laterally from a midline (M) of the cuff (10), which recess (100) is designed to receive the ulna bone (U) of said forearm (F) when said handle (30) is held by said hand (H) associated to said forearm (F). The cuff (10) may comprise a cushion (12), which is fastened to an inner side (11a) of a shell of the cuff (10), wherein the cushion (12) comprises said recess (100).
The invention relates to linear stabilized peptides, wherein one, two or more carboxamide functional groups located in the backbone are replaced by a 1,4-or 1,5-substituted 1,2,3- triazole, in particular, wherein the replaced carboxamide functional groups are at or near amide bond cleavage sites. These peptides have similar properties as the peptides from which they are derived, but show increased serum stability. Examples of peptides considered are receptor targeting peptides, such as regulatory peptides. Corresponding peptides carrying non-metallic radioisotopes, non-metallic and metallic dyes, paramagnetic metals, or radioactive metals are useful as diagnostic probes and/or therapeutic agents for cancer imaging and in cancer treatment.
The present invention relates to plasma-derived immunoglobulin for use in the treatment of immune reconstitution inflammatory syndrome (IRIS). Moreover, the present invention relates to a kit of parts for the treatment of IRIS comprising (a) plasma-derived immunoglobulin; (b) instructions for use to administer plasma-derived immunoglobulin in the treatment of IRIS.
The present invention is in the area of cancer treatment. In particular, the invention relates to chemotherapeutic compositions comprising immunoliposomes comprising an antibody or an antibody fragment, which recognizes and binds to an VEGF receptor (VEGFR) antigen on the surface of a tumor cell or a tumor-asscociated endothelial cell and further encapsulating in the liposome an anti-tumor compound, for treatment of cancer, particularly a cancer represented by a locally advanced or metastatic tumor, in an individual, particularly animal or human. The present invention also provides the use of such composition as a pharmaceutical composition.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
85.
METHODS AND SYSTEMS FOR THE PRODUCTION OF GRANULOSA CELLS
The present invention concerns methods and related cultured granulosa cells, assays and kits for drug discovery, therapeutic, and diagnostic purposes based on the discovery that granulosa cells cultured as monolayers remain viable in vitro over prolonged time periods, and exhibit stem cell potential when supplemented with leukaemia-inhibiting factor (LIF), and that use of a three-dimensional culture system such as type I collagen together with the use of LIF allows for both the survival and growth of preantral human GC while supporting a significant subpopulation of GC to maintain their characteristics for prolonged time periods, such as their ability to produce follicle-stimulating hormone receptor and cytochrome P450 aromatase.
To provide a diagnostic and therapeutic medicament, a bombesin analog peptide antagonist conjugate is provided which has general Formula (I): [A-(B)n]x-C, wherein A is a metal chelator comprising at least one radionuclide metal, B is a spacer linked to N-terminal of C or a covalent bond and C is a bombesin analog peptide antagonist having a sequence as claimed, where further x is an integer from 1 to 3 and n is an integer from 1 to 6.
The present invention relates to immunoliposomes for multiple treatment of human patients suffering from cancer, particularly a cancer represented by a locally advanced or metastatic tumor and to compositions used in said method. The invention further relates to the use of immunoliposomes for the treatment of multi-drug resistance in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
